跳转到主要内容
搜索

释放寡核苷酸疗法的力量:与 Certara 和 Ionis 合作,采用基于模型的方法

Oligonucleotide therapeutics are transforming drug development, but their complex pharmacology and regulatory landscape present unique challenges. Hear Certara and Ionis Pharmaceutical experts as we explore a model-informed approach to accelerating oligonucleotide drug development.

In this webinar, our experts covered:

  • Essential foundations of oligonucleotide therapeutics – what they are, how they work, and why they matter
  • Regulatory strategies for success from day one – ensuring alignment with evolving global expectations
  • How model-informed drug development (MIDD) accelerates and de-risks oligonucleotide programs – smarter decisions through data-driven insights

We showcased our collaboration with Ionis Pharmaceuticals, highlighting how our innovative modeling and regulatory strategies helped accelerate their oligonucleotide program. Through this real-world example, viewers gained insights into how Certara de-risks development, speeds approvals, and maximizes market access. Don’t miss the chance to learn from industry leaders and refine your oligonucleotide development strategy. Watch the webinar on demand now.

Access this resource

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software